Summary
SS-31 (Elamipretide) and MOTS-c both target mitochondria but through completely different mechanisms. SS-31 is a cardiolipin-binding antioxidant. MOTS-c is a mitochondrial-derived signalling peptide. Here is how they differ.
Overview
Both SS-31 and MOTS-c have attracted significant research interest for their potential to support mitochondrial health and address age-related decline in cellular energy function. Despite this shared focus, their mechanisms, research histories, and clinical development paths are quite different.
Quick Comparison
| SS-31 (Elamipretide) | MOTS-c | |
|---|---|---|
| Type | Synthetic tetrapeptide | Mitochondrial-derived hexadecapeptide |
| Primary target | Cardiolipin in inner mitochondrial membrane | Nuclear gene expression via AMPK |
| Mechanism | Antioxidant, electron transport chain protection | Metabolic signalling, insulin sensitivity |
| Key research areas | Cardiac failure, kidney protection, optic nerve | Metabolism, obesity, muscle aging |
| Clinical development | Phase 2/3 trials in cardiac failure (Elamipretide) | Early-stage human research |
| Administration | Subcutaneous injection | Subcutaneous injection |
How SS-31 Works
SS-31 (also known as Elamipretide or MTP-131) is a synthetic tetrapeptide developed by Dr. Hazel Szeto (Szeto-Schiller peptide family). It carries an alternating aromatic-cationic motif that allows it to penetrate cell membranes and concentrate in the inner mitochondrial membrane.
Its primary target is cardiolipin — a unique phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is essential for the structure and function of the electron transport chain (ETC). When cardiolipin is oxidised by reactive oxygen species (ROS), ETC complexes become disorganised and mitochondrial energy production falls.
SS-31 binds cardiolipin and:
- Prevents its oxidation
- Stabilises the architecture of ETC supercomplexes
- Reduces electron leak and ROS production
- Restores mitochondrial membrane potential
The result is improved ATP production efficiency in mitochondria that have been damaged by oxidative stress — particularly relevant in aged, diseased, or ischaemic tissue.
SS-31/Elamipretide has been in clinical trials for heart failure (HF-pEF — heart failure with preserved ejection fraction) and has also been studied for acute kidney injury, optic neuropathy, and Barth syndrome. It is among the most clinically advanced mitochondria-targeted compounds.
How MOTS-c Works
MOTS-c is a peptide encoded within the mitochondrial genome itself — a relatively recent discovery in mitochondrial biology. It is produced in mitochondria and released in response to metabolic stress or exercise, then travels to the nucleus.
In the nucleus, MOTS-c modulates the expression of genes involved in metabolism, particularly:
- Activating AMPK — a master energy sensor that promotes fat oxidation, inhibits anabolic pathways, and stimulates mitochondrial biogenesis
- Influencing the AICAR pathway — relevant to glucose and lipid metabolism
MOTS-c animal research has focused on:
- Obesity and insulin resistance (improved glucose uptake, fat oxidation)
- Exercise adaptation (circulating MOTS-c rises with physical activity)
- Muscle aging (reduced sarcopenia markers in aged mice)
- Lifespan extension (some murine longevity signals)
Human research is at an earlier stage than SS-31, though MOTS-c's circulating levels in humans correlate with age and exercise capacity, lending biological plausibility.
Key Distinction
The distinction worth internalising: SS-31 protects and repairs existing mitochondrial infrastructure. It is most relevant when mitochondria are under oxidative stress — in aged tissue, post-ischaemic tissue, or in high metabolic demand states.
MOTS-c enhances mitochondrial metabolic signalling. It is most relevant for metabolic regulation — improving how efficiently the body handles glucose and lipids, and how well it adapts to exercise.
They are not substitutes for each other. A researcher interested in cardiac or renal mitochondrial protection would reach for SS-31. A researcher focused on metabolic health and body composition would look primarily at MOTS-c.
Related Topics
Safety & Regulatory Note
Both SS-31 and MOTS-c are research peptides for laboratory use only. They are not approved medical treatments. This comparison is for educational purposes.
References
- 1.Szeto HH. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029–2050.
- 2.Lee C, et al. (2015). MOTS-c: A mitochondrial-derived peptide regulates muscle and fat metabolism. Cell Metabolism, 21(3), 443–454.
- 3.Alam NM, et al. (2015). A mitochondria-targeted drug improves vision in a murine model of traumatic optic neuropathy. Investigative Ophthalmology & Visual Science, 56(7), 4159–4166.
